Fluorescence in situ hybridization has become an essential detection assay in today´s routine diagnostics. However, long hybridization times of many hours to overnight are still a restrictive factor. We have refined the production process of our FISH probes to reduce background and artefacts and to improve the signal to noise ratio, particularly in short-time hybridization. Since mid-2015, one hour hybridization on lymphocytes is an integral part of quality control for all XCyting locus-specific probes at our manufacturing facility.
Break Apart Probe - Triple Color
- Order Number
- Package Size
- 100 µl
The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2008) cytogenetic aberrations are observed in about 50 % of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3;3).
Chromosomal translocations involving the MECOM locus are a recurrent finding in myeloid leukemia and are associated with poor prognosis. Two common recurrent rearrangements affect the 3q26 locus. One is the inv(3)(q21q26) and the translocation t(3;3)(q21;q26), in which EVI1 overexpression is caused by juxtaposition of the EVI1 gene to enhancer elements of the Ribophorin gene at 3q21. EVI1 activation is also observed in the translocations t(3;12)(q26;p13) and t(3;21)(q26;q22) and is due to generation of the fusion genes ETV6/EVI1 and RUNX1/EVI1, respectively.
- Myelodysplastic Syndrome (MDS)
- Acute Myelogenous Leukemia (AML)
Two blue-green-orange (2BGO) fusion signals representing the two normal EVI1 loci.
Aberrant Cell (typical results):
One green-blue (1GB) signal and one separate orange (1O) signal from the translocated chromosome and one blue-green-orange (1BGO) fusion signal from the normal chromosome.
Aberrant Cell (typical results): One green-orange (1GO) signal and one separate blue (1B) signal from the translocated chromosome and one blue-green-orange (1BGO) fusion signal from the normal chromosome.
- De Melo et al (2007) Leukemia 22:434-437
- De Wer et al (2008) Haematologica 93:1903-1907
- De Braekeleer et al (2015) Future Oncology 11:1675-1686